Creative Touch Permanent Makeup and Aesthetics

Protease-activated receptor 2 (PAR2) is one of the skin’s most important molecular sensors – a receptor that does not wait for cytokines or pattern recognition molecules to report what is happening at the barrier. It reads the protease environment directly: when serine proteases are present at the skin surface or within the epidermis at abnormal concentrations, PAR2 is activated by their catalytic activity, and the downstream consequences are immediate, pleiotropic, and, in the context of dysregulated protease activity, damaging.

In healthy skin, controlled PAR2 activation by physiological KLK concentrations contributes to barrier repair, keratinocyte differentiation in the granular layer, and innate antimicrobial responses. In disease states – rosacea, atopic dermatitis, acne, Netherton syndrome – excess KLK5, KLK14, C. acnes proteases, or mast cell tryptase drives PAR2 beyond homeostatic activation into a sustained signalling state that generates TSLP-driven Th2 skewing, NF-κB-mediated cytokine production, lamellar body secretion inhibition delaying barrier repair, and neurogenic itch through TRPV3/TRPV1/TRPA1 sensory neuron activation. The neuroimmune dimension is what makes PAR2 genuinely distinct from the other inflammatory signalling receptors in this knowledge base: it connects the protease excess of barrier-disrupted skin directly to the itch-scratch cycle, which generates its own barrier damage and sustains the protease exposure that drives further PAR2 activation. Understanding PAR2 is understanding how barrier disruption, inflammation, and itch are mechanistically the same loop – not three separate problems. ^[4]

PAR2 belongs to the protease-activated receptor family – four G protein-coupled receptors (PAR1, PAR2, PAR3, PAR4) that share an unusual activation mechanism unlike any other GPCR. Most GPCRs are activated by ligands binding from the extracellular space. PARs are activated by serine proteases cleaving their own extracellular N-terminus – unmasking a tethered ligand sequence that then folds back to bind the receptor’s own binding pocket in cis, triggering intracellular signalling. The receptor, in effect, activates itself once the protease has done the initial cut. ^[1]

The consequence of this architecture is that PAR2 does not respond to a specific molecule – it responds to serine protease activity in its environment. Any serine protease capable of cleaving the specific Arg36-Ser37 bond in PAR2’s N-terminal exodomain can activate it. The physiological activators in skin include KLK5, KLK14, mast cell tryptase, and neutrophil elastase. The pathological activators include allergen-derived serine proteases (Der p1, Der p3 from house dust mite), Staphylococcus aureus V8 protease/GluSE, and C. acnes proteases. Once activated, the receptor cannot be “switched off” by removing the protease – the tethered ligand is already bound. Signalling continues until the receptor is internalised and degraded, which is why excess PAR2 activation produces sustained rather than transient downstream effects. ^[4]

Expression in skin

PAR2 is expressed broadly across skin cell types, with distinct functional consequences at each site:

Keratinocytes – the primary cellular context in skin biology. PAR2 is most strongly expressed in the granular layer of the epidermis, where it co-localises with the LEKTI/KLK5 regulatory axis operating in the stratum corneum immediately above. The spatial alignment is not coincidental: the granular layer keratinocytes producing LEKTI and secreting hCAP18 are the cells most directly exposed to the consequences of KLK5 dysregulation, and PAR2 is the receptor through which that dysregulation is translated into cellular inflammatory signalling. ^[1]

Sebocytes – PAR2 expression in sebaceous glands positions it as an innate immune receptor in the sebaceous follicle, relevant to acne pathogenesis. Enhanced PAR2 immunoreactivity is found in the vicinity of comedones in acne-affected skin, and PAR2 activation in sebocytes by C. acnes proteases drives IL-8, TNF-α, and hBD-2 production – an innate immune activation pathway distinct from the TLR2 route through which C. acnes is more commonly discussed. ^[4]

Sensory neurons – PAR2 expressed on cutaneous sensory nerve fibres is the receptor mediating neurogenic itch and neurogenic inflammation in multiple skin conditions. This is the dimension that makes PAR2 mechanistically distinct from most of the receptors elsewhere in this knowledge base: it operates across the neuroimmune interface, connecting protease activity in the epidermis to sensory signalling in the peripheral nervous system in a direct, receptor-mediated pathway. ^[2]

Mast cells – PAR2 expression on mast cells means that mast cell tryptase – released during mast cell degranulation – can activate PAR2 on adjacent keratinocytes and sensory neurons. Mast cell tryptase is both a product of mast cell activation and, through PAR2, a driver of further keratinocyte inflammation and neurogenic signalling. The mast cell/PAR2 interaction is a self-amplifying loop: mast cell activation releases tryptase → tryptase activates PAR2 → PAR2 promotes TSLP production → TSLP activates further mast cell degranulation. ^[4]

PAR2 in barrier homeostasis – the context-dependent role

PAR2’s effects on skin barrier function are genuinely contradictory depending on the activation context.

Acute controlled activation – barrier repair contribution. Application of SLIGRL (a synthetic exogenous PAR2 agonist) at controlled doses in intact skin protects and accelerates barrier repair. PAR2 activation in keratinocytes initiates cytoskeletal rearrangements and plasma membrane dynamics changes that support barrier repair responses – including tight junction modulation and lamellar body positioning. At physiological protease concentrations, PAR2 appears to function as a damage sensor that initiates coordinated repair responses. ^[1]

PAR2 activation also promotes keratinocyte differentiation when the barrier is compromised – an important homeostatic function, since differentiation drives the structural protein production (including filaggrin, loricrin, and involucrin) that rebuilds the cornified envelope. PAR2 agonist treatment increases loricrin and filaggrin expression in cultured keratinocyte models, suggesting a physiological role in differentiation signalling at barrier breach sites. ^[1]

Excess or sustained activation – barrier disruption. At the elevated protease concentrations characteristic of inflammatory disease states, PAR2 activation delays barrier recovery by inhibiting lamellar body secretion. Lamellar bodies contain the lipid precursors – glucosylceramides, phospholipids, fatty acids – that are secreted into the stratum corneum intercellular spaces to form the barrier lipid lamellae. PAR2 activation by the SLIGRL agonist peptide at higher doses inhibits this secretion, directly impairing the barrier lipid matrix formation required for recovery after disruption. ^[1]

Unregulated KLK5 – as in SPINK5-null Netherton syndrome – directly activates PAR2 and induces NF-κB-mediated overexpression of TSLP, ICAM-1, TNF-α, and IL-8, increasing epidermal permeability and exacerbating barrier defects. The SPINK5/PAR2 double-knockout (DKO) mice generated by Briot et al. confirmed this causal chain: the barrier defects and inflammatory parameters of SPINK5-null mice were substantially attenuated when PAR2 was simultaneously deleted, establishing PAR2 as a required downstream mediator – not merely an associated signal – of the KLK5-driven pathology in Netherton syndrome. ^[1]

The barrier dual role is not a scientific contradiction. It is a dose-response relationship. Controlled PAR2 activation at physiological protease concentrations = repair signal. Sustained or excess PAR2 activation at dysregulated protease concentrations = barrier destruction amplifier. The receptor is doing its job in both cases. The pathology lies in the protease excess that drives it beyond the repair-promoting range.

The NF-κB axis: TSLP, ICAM-1, TNF-α, and IL-8

When KLK5 or KLK14 activate PAR2 in keratinocytes, the primary intracellular signalling cascade runs through NF-κB – the same transcription factor at the centre of the inflammatory amplification loop in acne, AD, and rosacea. PAR2-driven NF-κB activation produces a specific cytokine signature: ^[4]

TSLP (Thymic Stromal Lymphopoietin) – the most clinically significant downstream product of PAR2 activation in skin. TSLP is the epithelial-derived alarmin that drives Th2 skewing by activating dendritic cells and mast cells to produce IL-4, IL-13, and IL-5 promoting cytokines. TSLP also directly activates basophil accumulation and stimulates PAR2, TRPV1, and TRPA1 in sensory neurons – creating the itch-promoting neuroimmune signal described below. In the context of PAR2 biology, TSLP is the bridge between protease-driven innate immune activation and the adaptive Th2 immune response of atopic disease. KLK5 → PAR2 → TSLP → Th2 is the mechanistic route by which a dysregulated epidermal protease becomes the upstream driver of adaptive immune polarisation in AD. ^[4]

ICAM-1 – intercellular adhesion molecule 1, facilitating leukocyte recruitment to the activated keratinocyte. PAR2-driven ICAM-1 upregulation promotes neutrophil and T cell adhesion to the epidermis – sustaining cellular inflammatory infiltration in chronically activated presentations.

TNF-α and IL-8 – pro-inflammatory mediators that amplify the NF-κB signalling environment, promote mast cell degranulation, and recruit further immune effector cells. IL-8 in particular is a potent neutrophil chemoattractant – relevant in acne, where C. acnes CAMP factor-driven IL-8 production is the primary mechanism of neutrophil recruitment to inflammatory lesions, and PAR2 adds a second, protease-activated route to the same IL-8 signal.

PAR2 and itch – the neuroimmune pathway

The neurogenic dimension of PAR2 is what distinguishes it from most other receptors in epidermal biology, and it is directly relevant to the itch-scratch cycle that sustains and worsens AD and other pruritic conditions.

PAR2 expressed on cutaneous sensory neurons – specifically on TRPV1- and TRPA1-expressing C-fibres and Aδ-fibres – is activated by serine proteases present in inflamed skin, including KLK5, mast cell tryptase, and allergen-derived proteases. Activation triggers intracellular PLC-Ca²⁺ signalling in the sensory neuron, releasing substance P (SP) and Calcitonin Gene-Related Peptide (CGRP) from peripheral nerve terminals. ^[2]

SP and CGRP produce neurogenic inflammation: vasodilation, plasma protein extravasation, mast cell degranulation, and further protease release – which activates more PAR2 on adjacent keratinocytes and neurons. The neurogenic amplification loop runs independently of the adaptive immune response. It does not require T cells or IgE. It requires only protease activity at sensory nerve terminals and functional PAR2 expression on those fibres. ^[2]

The TRPV3 itch route. A parallel PAR2-mediated itch pathway runs through TRPV3 – a warm temperature-sensitive calcium channel abundantly expressed in cutaneous keratinocytes. PAR2 activation in keratinocytes triggers TRPV3 opening, producing a TSLP release that then stimulates TRPV1 and TRPA1 on adjacent sensory neurons. This keratinocyte-to-neuron itch signal is distinct from the direct PAR2 activation of sensory neurons described above – it is mediated by TSLP as an intermediary between epidermal PAR2 signalling and sensory fibre activation. ^[4]

The clinical consequence: enhanced PAR2 signalling has been identified as a direct mechanistic link between the inflammatory and sensory phenomena in AD – not a correlation, a causal pathway. Increased protease activity in AD lesional skin activates PAR2 on both keratinocytes (producing TSLP → TRPV1/TRPA1 in neurons) and directly on sensory fibres (producing SP/CGRP release), creating a compounded itch signal that drives scratching – which in turn disrupts the barrier, increases transepidermal protease exposure, and further activates PAR2. The itch-scratch cycle is, at its molecular centre, a PAR2/protease positive feedback loop. ^[6]

PAR2 across skin conditions

Rosacea. A positive correlation between PAR2 expression and cathelicidin levels has been confirmed in rosacea patients. PAR2-activating peptides in keratinocyte cultures increase both cathelicidin (LL-37) and VEGF production – suggesting that PAR2 activation in the rosacea epidermis not only responds to KLK5 excess but actively amplifies the same LL-37 and vascular pathway that KLK5 dysregulation is driving. The LEKTI-mimetic compound lead 7 (described in the LEKTI entity) suppresses KLK5-mediated PAR2 activation – establishing PAR2 as the downstream mediator of KLK5’s pathological signalling in rosacea, and as a target for future therapeutic inhibition. ^[5]

Atopic dermatitis. KLK5, KLK7, KLK8, and KLK14 have all been detected in the perspiration of AD patients – elevated serine protease activity that drives PAR2 activation throughout AD-affected skin. KLK5-driven PAR2 → TSLP production is the specific mechanism linking the barrier protease dysregulation of AD to the Th2 cytokine environment that defines the condition’s immunological character. In the SPINK5/PAR2 DKO experiment, PAR2 deletion attenuated the Th2 skewing and inflammatory parameters of SPINK5-null skin – confirming PAR2 as the required intermediary between KLK dysregulation and Th2 adaptive immune polarisation. ^[1]

Acne vulgaris. PAR2 levels are higher in keratinocytes and sebaceous glands of acne lesional skin compared with non-lesional skin. C. acnes culture supernatant activates PAR2-mediated calcium signalling in keratinocytes and upregulates IL-1α, IL-8, TNF-α, hBD-2, LL-37, and MMP-1, -2, -3, -9, and -13. In sebocytes specifically, PAR2 activation drives IL-8 and TNF-α production – positioning it as a sebaceous innate immune receptor activated by C. acnes proteases in the follicular environment, parallel to and compounding the TLR2 activation route. Retinoids negatively regulate PAR2 expression in keratinocytes – providing a further mechanistic rationale for retinoid therapy in acne beyond their follicular hyperkeratinisation correction. ^[4]

Psoriasis. PAR2 contributes to psoriatic inflammation through keratinocyte NF-κB activation and leukocyte recruitment. Its expression is elevated in psoriatic plaques and its activation amplifies the IL-8 and TNF-α production characteristic of psoriatic lesional skin. The role here is part of the broader inflammatory amplification picture rather than a primary pathogenic driver – but PAR2 inhibition has been studied as a potential adjunct approach in psoriasis models.

PAR2 inhibition – the therapeutic landscape

No PAR2 antagonist is currently licensed for a skin indication, but the pathway is well-validated as a therapeutic target. Several approaches are at different development stages:

Doxycycline – indirect PAR2 inhibition. Tetracyclines reduce cutaneous inflammation partly through attenuation of the PAR2/IL-8 axis in keratinocytes. Doxycycline also indirectly inhibits KLK5 and KLK14 production by reducing MMP secretion – since MMPs can activate KLK zymogens, reducing MMPs reduces the KLK activity available to activate PAR2. This adds a PAR2-indirect mechanism to doxycycline’s already-established KLK5 protein-level inhibition and NF-κB suppression. ^[1]

Azelaic acid. By suppressing KLK5 mRNA and protein expression, azelaic acid reduces the primary PAR2 activator in rosacea skin – an indirect PAR2 suppression strategy operating through reduced substrate availability rather than receptor-level antagonism.

LEKTI-mimetic therapeutics. The lead 7 SFTI-LEKTI compound specifically suppresses KLK5-mediated PAR2 activation – established in NS keratinocyte functional studies. The PAR2 suppression is a direct translational benefit of LEKTI-mimetic therapy beyond its corneodesmosomal protection and LL-37 normalisation effects. ^[3]

Direct PAR2 antagonists. Several small-molecule PAR2 antagonists have been characterised in research settings, with GB88 and FSLLRY-NH2 among the most studied. None have reached clinical dermatology use – the challenge is that PAR2 inhibition at the receptor level would suppress both the pathological excess activation and the physiologically protective controlled activation that contributes to barrier repair. Partial agonism or biased agonism approaches – favouring the repair-promoting signalling arms of PAR2 while suppressing the NF-κB/TSLP inflammatory arms – represent the conceptually most elegant therapeutic direction, though this remains at research stage. ^[1]